Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 0.78 |
| ▸ | MAOB | P27338 | 3/20 | 0.78 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.76 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.76 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.76 |
| ▸ | PPARA | Q07869 | 1/20 | 0.69 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442111 | 0.88 | MAOB (0.76) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL2088610 | 0.88 | MAOB (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL30417785 | 0.88 | MAOB (0.76) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL22481084 | 0.86 | MRGPRX4 (1.00) | NR4A2MRGPRX4PPARASMN1; SMN2 | |
| SCHEMBL7052396 | 0.86 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL2087017 | 0.86 | MAOB (0.70) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL17969089 | 0.85 | MAOB (0.73) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL28056060 | 0.85 | MAOB (0.77) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL22480781 | 0.85 | MRGPRX4 (1.00) | NR4A2MAOBMRGPRX4 | |
| SCHEMBL1168262 | 0.84 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | NR4A2 2332/4885MAOB 396/4885MRGPRX4 4394/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | NR4A2 3157/4885MAOB 2736/4885MRGPRX4 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.